File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Development of subunit vaccines against severe acute respiratory syndrome

TitleDevelopment of subunit vaccines against severe acute respiratory syndrome
Authors
Issue Date2008
PublisherProus Science. The Journal's web site is located at PHARMACY AND PHARMACOLOGY
Citation
Drugs of Today, 2008, v. 44 n. 1, p. 63-73 How to Cite?
AbstractSevere acute respiratory syndrome (SARS) is a novel infectious disease caused by SARS coronavirus (SARS-CoV). Although SARS appears to have been successfully contained, there is still a risk for its reemergence due to sporadic laboratory accidents or the presence of a natural reservoir for SARS-CoV-like virus. Therefore, the development of effective vaccines against SARS-CoV continues to be the current focus of SARS research. This review will first describe the rationale for developing safe and effective SARS vaccines, followed by elucidating viral antigens that could be used as potential vaccine components. After comparing current vaccine categories against SARS, this article will demonstrate the advantages of subunit vaccines, describe the current situation of developing subunit vaccines, and point out the possibility for further improvement of subunit SARS vaccines. This suggests that recombinant protein/peptide-based subunit vaccines containing the spike protein, especially the receptor-bind domain of SARS-CoV, could be developed as safe and effective SARS vaccines. © 2008 Prous Science, S.A.U. or its licensors. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/157511
ISSN
2015 SCImago Journal Rankings: 0.402
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorDu, Len_US
dc.contributor.authorHe, Yen_US
dc.contributor.authorJiang, Sen_US
dc.contributor.authorZheng, Ben_US
dc.date.accessioned2012-08-08T08:50:44Z-
dc.date.available2012-08-08T08:50:44Z-
dc.date.issued2008en_US
dc.identifier.citationDrugs of Today, 2008, v. 44 n. 1, p. 63-73en_US
dc.identifier.issn1699-4019en_US
dc.identifier.urihttp://hdl.handle.net/10722/157511-
dc.description.abstractSevere acute respiratory syndrome (SARS) is a novel infectious disease caused by SARS coronavirus (SARS-CoV). Although SARS appears to have been successfully contained, there is still a risk for its reemergence due to sporadic laboratory accidents or the presence of a natural reservoir for SARS-CoV-like virus. Therefore, the development of effective vaccines against SARS-CoV continues to be the current focus of SARS research. This review will first describe the rationale for developing safe and effective SARS vaccines, followed by elucidating viral antigens that could be used as potential vaccine components. After comparing current vaccine categories against SARS, this article will demonstrate the advantages of subunit vaccines, describe the current situation of developing subunit vaccines, and point out the possibility for further improvement of subunit SARS vaccines. This suggests that recombinant protein/peptide-based subunit vaccines containing the spike protein, especially the receptor-bind domain of SARS-CoV, could be developed as safe and effective SARS vaccines. © 2008 Prous Science, S.A.U. or its licensors. All rights reserved.en_US
dc.languageengen_US
dc.publisherProus Science. The Journal's web site is located at PHARMACY AND PHARMACOLOGY-
dc.relation.ispartofDrugs of Todayen_US
dc.subject.meshAnimalsen_US
dc.subject.meshDrug Designen_US
dc.subject.meshHumansen_US
dc.subject.meshMembrane Glycoproteins - Immunologyen_US
dc.subject.meshSars Virus - Immunologyen_US
dc.subject.meshSevere Acute Respiratory Syndrome - Prevention & Controlen_US
dc.subject.meshVaccines, Subuniten_US
dc.subject.meshViral Envelope Proteins - Immunologyen_US
dc.subject.meshViral Vaccinesen_US
dc.titleDevelopment of subunit vaccines against severe acute respiratory syndromeen_US
dc.typeArticleen_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_US
dc.identifier.authorityZheng, BJ=rp00353en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1358/dot.2008.44.1.1131830en_US
dc.identifier.pmid18301805-
dc.identifier.scopuseid_2-s2.0-40849120656en_US
dc.identifier.hkuros142912-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40849120656&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume44en_US
dc.identifier.issue1en_US
dc.identifier.spage63en_US
dc.identifier.epage73en_US
dc.identifier.isiWOS:000253889500007-
dc.identifier.scopusauthoridDu, L=8686996200en_US
dc.identifier.scopusauthoridHe, Y=8742157400en_US
dc.identifier.scopusauthoridJiang, S=7404453146en_US
dc.identifier.scopusauthoridZheng, BJ=7201780588en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats